Table 6.
Results of intratumoral chemotherapy for locally advanced pancreatic cancer
| Reference | n | Metastasis | Type of intratumoral CHT | Intratumoral CHT dose (mg), median* (range) | Combination therapy | Overall complications, n | Complications ≥grade III | Median* survival (months); OS initiation | NOS 1–9 |
|---|---|---|---|---|---|---|---|---|---|
| Levy et al., 201173 | 36 | 11 (30) | Gemcitabine | 90 (28–280) | CRT 36 (100) | 0 | 0 (0) | 9.3; T | 5 |
| Li et al., 201674 | 18 | NR | 5-Fluorouracil capsule | (800–1500) | CHT 18 (100) | NR | NR | 10.3 | 7† |
| Mohamadnejad et al., 201575 | 12 | 0 (0) | Gemcitabine | 168 (80–200) | CHT (NR), CRT (NR) | NR | 0 (0) | 9 | 8 |
| Yang et al., 201776 | 5 | 4 (80) | Gemcitabine | (400–600) | NR | 3 | 0 (0) | 16.2 | 7 |
| Cisplatin | (11.25–22.5) | ||||||||
| Total | 71 | 15 of 53 (28) | NA | NA | CHT 18 (33), CRT 36 (67) | 3 of 41 | 0 of 53 (0) | NA | NA |
Values are n (%) unless otherwise stated. *If the median was unavailable the mean is presented. †RCT. CHT, chemotherapy; OS, overall survival; NOS, Newcastle–Ottawa scale; CRT, chemoradiotherapy; T, treatment; NR, not reported; NA, not applicable.